Bausch Health Americas, Inc is evaluating Amiselimod (MT-1303) in Ulcerative Colitis


The condition is Ulcerative Colitis.

A new clinical trial is recruiting patients in the following locations: United States.

The trial officially began in April 2021 and is planned to complete on October 2023.

The study will assess the efficacy and safety of oral MT-1303 compared to placebo at 12 weeks as the induction treatment in subjects with active mild to moderate ulcerative colitis (UC), as well as maintenance treatment with open-label MT-1303 for up to 36 weeks.

The link to the complete study profile:

Clinical Research News

Upcoming Clinical Trials